Prescription drug

Efforts to Protect Lipitor from Generic Competition: Cause for Concern?

Posted on 06/20/2013 by |AARP Blog Author | Comments

Personal Health | Public Policy InstituteA new Rx Price Watch report examines the strategies reportedly used by Pfizer to try to maintain revenue and market share for its popular anti-cholesterol drug Lipitor as its patent expired. Pfizer’s tactics raise important concerns for consumers and publicly funded programs like Medicare. The patent for Lipitor was originally expected to expire no later than June 2011 after 14 years on the market. In response, Pfizer reportedly developed an unprecedented strategy to protect and extend Lipitor sales, which included: …

Got Generics? New Studies Show Their Price Is Dropping

Posted on 07/21/2011 by |Personal Health and Well-being | Comments

Bulletin Today | Money & SavingsIf you use generic prescription drugs, you’ll be happy to know that you paid nearly 8 percent less for them in 2009, according to a new report  from AARP’s Public Policy Institute. Even better news: A new industry-funded report says the trend toward cheaper prescription generic drugs will continue through 2015. That’s a double-dose of good news for seniors approaching the Medicare drug coverage gap known as the dreaded doughnut hole. Up to 4.5 million seniors will fall into the Part …